We are analyzing https://link.springer.com/article/10.1007/s10555-024-10232-4.

Title:
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer | Cancer and Metastasis Reviews
Description:
Cellular and targeted immunotherapies have revolutionized cancer treatments in the last several decades. Successful cellular therapies require both effective and durable cytotoxic activity from the immune cells as well as an accessible and susceptible response from targeted cancer cells. Correlative studies from clinical trials as well as real-world data from FDA-approved therapies have revealed invaluable insights about immune cell factors and cancer cell factors that impact rates of response and relapse to cellular therapies. This review focuses on the flagship cellular therapy of engineered chimeric antigen receptor T-cells (CAR-T cells). Within the CAR-T cell compartment, we discuss discoveries about T-cell phenotype, transcriptome, epigenetics, cytokine signaling, and metabolism that inform the cell manufacturing process to produce the most effective and durable CAR-T cells. Within the cancer cell compartment, we discuss mechanisms of resistance and relapse caused by mutations, alternative splicing, post-transcriptional modifications, and cellular reprogramming. Continued correlative and mechanistic studies are required to help us further optimize cellular therapies in a variety of malignancies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cell, car, cells, cancer, nature, cart, therapy, leukemia, journal, medicine, article, antigen, httpsdoiorgs, blood, tcell, acute, lymphoblastic, resistance, chimeric, receptor, immunotherapy, mackall, discovery, wang, pubmed, zhang, therapies, clinical, relapse, bcell, patients, chen, factors, cellular, oncology, lymphoma, shah, scholar, function, england, children, young, httpsdoiorgblood, sadelain, google, httpsdoiorgsz, ball, research, tisagenlecleucel, cas,

Topics {✒️}

/suv39h1-ablation-enhances-long-term-car-t-function weber suv39h1-mediated-h3k9-methylation lópez-cobo target-antigen-density-improves-car jacoby cd34+cd19−cd22+ b-cell progenitors 010/attachment/92e3fa39-8112-4573-a1f5-8d938b787c95/mmc3 cd19 car-t-cell therapy decade-long leukaemia remissions myeloid lineage switch anti-gd2 car t-cells genome-wide crispr screens acute lymphoblastic leukaemia month download article/chapter car t-cell cytotoxicity car t-cell therapy anti-cd19/cd3 bite kmt2a-rearranged acute leukemia long-duration complete remissions b-cell lymphoblastic leukemia refractory b-cell lymphoma cd19-negative myeloid phenotype unchecked batf3-induced car intraventricular b7-h3 car refractory high-risk neuroblastoma chimeric antigen receptor central memory cells anti-cd19-targeted immunotherapies long-term follow recurrent high-grade glioma cells targeting b7-h3 real-world data durable cytotoxic activity immune cell factors t-cell phenotype acute lymphoblastic leukemia nr4a transcription factors induces adaptive resistance t-cell therapies orthogonal crispr screens cd19-targeted car immunotherapy target antigen loss target tumor killing cd19 enables resistance generate receptor-engineered integrated drug profiling il-13rα2-targeting car cd19-directed therapies metastasis reviews aims car t-cells cancer cell factors vivo culture improves

Questions {❓}

Will CAR T cell therapy have a role in AML?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer
         description:Cellular and targeted immunotherapies have revolutionized cancer treatments in the last several decades. Successful cellular therapies require both effective and durable cytotoxic activity from the immune cells as well as an accessible and susceptible response from targeted cancer cells. Correlative studies from clinical trials as well as real-world data from FDA-approved therapies have revealed invaluable insights about immune cell factors and cancer cell factors that impact rates of response and relapse to cellular therapies. This review focuses on the flagship cellular therapy of engineered chimeric antigen receptor T-cells (CAR-T cells). Within the CAR-T cell compartment, we discuss discoveries about T-cell phenotype, transcriptome, epigenetics, cytokine signaling, and metabolism that inform the cell manufacturing process to produce the most effective and durable CAR-T cells. Within the cancer cell compartment, we discuss mechanisms of resistance and relapse caused by mutations, alternative splicing, post-transcriptional modifications, and cellular reprogramming. Continued correlative and mechanistic studies are required to help us further optimize cellular therapies in a variety of malignancies.
         datePublished:2024-12-03T00:00:00Z
         dateModified:2024-12-03T00:00:00Z
         pageStart:1
         pageEnd:13
         sameAs:https://doi.org/10.1007/s10555-024-10232-4
         keywords:
            CAR-T cell therapies
            Cancer
            Correlative studies
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-024-10232-4/MediaObjects/10555_2024_10232_Fig1_HTML.png
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:44
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Catherine D. Yao
               url:http://orcid.org/0000-0001-5740-2308
               affiliation:
                     name:Stanford University
                     address:
                        name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kara L. Davis
               url:http://orcid.org/0000-0002-7182-2592
               affiliation:
                     name:Stanford University
                     address:
                        name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
                        type:PostalAddress
                     type:Organization
                     name:Stanford University
                     address:
                        name:Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer
      description:Cellular and targeted immunotherapies have revolutionized cancer treatments in the last several decades. Successful cellular therapies require both effective and durable cytotoxic activity from the immune cells as well as an accessible and susceptible response from targeted cancer cells. Correlative studies from clinical trials as well as real-world data from FDA-approved therapies have revealed invaluable insights about immune cell factors and cancer cell factors that impact rates of response and relapse to cellular therapies. This review focuses on the flagship cellular therapy of engineered chimeric antigen receptor T-cells (CAR-T cells). Within the CAR-T cell compartment, we discuss discoveries about T-cell phenotype, transcriptome, epigenetics, cytokine signaling, and metabolism that inform the cell manufacturing process to produce the most effective and durable CAR-T cells. Within the cancer cell compartment, we discuss mechanisms of resistance and relapse caused by mutations, alternative splicing, post-transcriptional modifications, and cellular reprogramming. Continued correlative and mechanistic studies are required to help us further optimize cellular therapies in a variety of malignancies.
      datePublished:2024-12-03T00:00:00Z
      dateModified:2024-12-03T00:00:00Z
      pageStart:1
      pageEnd:13
      sameAs:https://doi.org/10.1007/s10555-024-10232-4
      keywords:
         CAR-T cell therapies
         Cancer
         Correlative studies
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-024-10232-4/MediaObjects/10555_2024_10232_Fig1_HTML.png
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:44
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Catherine D. Yao
            url:http://orcid.org/0000-0001-5740-2308
            affiliation:
                  name:Stanford University
                  address:
                     name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kara L. Davis
            url:http://orcid.org/0000-0002-7182-2592
            affiliation:
                  name:Stanford University
                  address:
                     name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
                     type:PostalAddress
                  type:Organization
                  name:Stanford University
                  address:
                     name:Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:44
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Stanford University
      address:
         name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
         type:PostalAddress
      name:Stanford University
      address:
         name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
         type:PostalAddress
      name:Stanford University
      address:
         name:Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Catherine D. Yao
      url:http://orcid.org/0000-0001-5740-2308
      affiliation:
            name:Stanford University
            address:
               name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
               type:PostalAddress
            type:Organization
      name:Kara L. Davis
      url:http://orcid.org/0000-0002-7182-2592
      affiliation:
            name:Stanford University
            address:
               name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
               type:PostalAddress
            type:Organization
            name:Stanford University
            address:
               name:Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
      name:Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, USA
      name:Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(165)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.78s.

LINK . SPRINGER . COM {}